Related Experiment Video
Updated: Jan 15, 2026

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
Published on: January 26, 2019
Clinical progress note: Respiratory syncytial virus
Justin B Searns1,2, Sean T O'Leary2
1Department of Pediatrics, Section of Hospital Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.
Abstract:
Globally, respiratory syncytial virus (RSV) is responsible for more than 3.6 million hospitalizations and 100,000 deaths every year. Since 2023, three immunizations have been approved for clinical use, each targeting a different patient population. These newly available RSV immunizations are poised to prevent hospitalizations, reduce costs for healthcare systems, and save lives. This review will discuss the evidence behind these immunization strategies and examine their potential to blunt the global impact from RSV.
More Related Videos
Related Concept Videos
Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Acute Respiratory Failure-I
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Acute Respiratory Failure-III
Common Respiratory Disorders
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
Pneumonia III: Complications and Assessment

